|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Center for Medicinal Cannabis Research |
|---|---|
| Information provided by: | Center for Medicinal Cannabis Research |
| ClinicalTrials.gov Identifier: | NCT00046722 |
Purpose
To evaluate whether smoked marijuana reduces pain in people with HIV-related peripheral neuropathy.
| Condition | Intervention | Phase |
|---|---|---|
|
Peripheral Nervous System Diseases HIV Infections |
Drug: Smoked Marijuana |
Phase I Phase II |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Effects of Marijuana on Neuropathic Pain in HIV-Related Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study. |
| Estimated Enrollment: | 50 |
| Study Start Date: | January 2003 |
| Estimated Study Completion Date: | April 2005 |
The study will include subjects with peripheral neuropathy caused either by HIV-disease or antiretroviral medication for the treatment of HIV. A neurologist will conduct a neurological and pain evaluation to determine eligibility for the study. Subjects who meet all eligibility criteria will be admitted to the General Clinical Research Center at San Francisco General Hospital for seven days. Subjects will be randomized (like a toss of a coin) to smoke marijuana or a placebo (cigarettes with no THC).
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
EXCLUSION CRITERIA: (Not allowed)
Contacts and Locations| United States, California | |
| University of California, San Francisco Community Consortium | |
| San Francisco, California, United States, 94110 | |
| Principal Investigator: | Donald I Abrams, M.D. | UCSF Community Consortium |
More Information
| ClinicalTrials.gov Identifier: | NCT00046722 History of Changes |
| Other Study ID Numbers: | C00-SF-101, CC# 056 |
| Study First Received: | October 1, 2002 |
| Last Updated: | June 12, 2007 |
| Health Authority: | United States: Food and Drug Administration |
|
treatment experienced complementary therapies Neuropathy |
Peripheral Neuropathy HIV-Related Peripheral Neuropathy HIV |
|
HIV Infections Acquired Immunodeficiency Syndrome Nervous System Diseases Peripheral Nervous System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections |
Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Neuromuscular Diseases |